Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 19;211(3):239–247. doi: 10.1093/cei/uxad005

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)

PMC Copyright notice

Figure 3. — HCQ treatment reduces circulating CitH3 levels in PDAC patients. (a) Patients with pancreatic adenocarcinoma were enrolled in a randomized clinical trial of neoadjuvant gemcitabine/nab-paclitaxel plus HCQ versus gemcitabine/nab-paclitaxel alone. CitH3 concentration was measured in patient plasma using ELISA and pre treatment (pre-neoadjuvant) versus post treatment (post-neoadjuvant) concentration was compared in the chemotherapy only (n = 26) and the chemotherapy plus HCQtreatment groups (n = 27). There was a significant reduction in CitH3 in patients treated with chemotherapy plus HCQ. (b) Median change of CitH3 levels in the chemotherapy versus chemotherapy + HCQ treatment group demonstrating reduction in CitH3 in the chemotherapy +_HCQ group (P value = 0.01). Whisker bars represent the range of minimum and maximum within each group.